Pro Bono Bio wraps round of hemophilia trials; Eaton develops first non-hormonal menopause patch;

> Pro Bono Bio has completed its first series of trials of subcutaneous treatments for hemophilia, showing that the therapies improve blood clotting for extended periods. These would make self-administration of blood-clotting factors simpler and reduce the need for intravenous infusions, potentially improving compliance and cutting healthcare costs. Press release

> Eaton Scientific Systems is developing a transdermal patch to deliver homatropine for non-hormonal treatment of hot flashes in menopausal women. According to the company, this will be the world's first prescription non-hormonal transdermal treatment for hot flashes. Press release

> India-based Panacea Biotec has tied up with drug delivery company Osmotica Pharmaceutical to create generic and branded formulations for global markets. Article

> The African University of Science and Technology (AUST) is developing a nanoparticle-delivered formulation of a chemotherapeutic derived from bacteria, prodigosene, as a cancer drug, and animal studies are planned for next year. Article

> Neuralstem has licensed its spinal cord delivery platform and floating cannula, for delivering therapeutic agents to the spinal cord, to Q Therapeutics. Financial terms were not disclosed. Press release

> OncoSec Medical has licensed electroporation technology from the University of South Florida Research Foundation (USFRF). Article

> Indian company Opto Eurocor Healthcare has launched E-MAGIC, a sirolimus drug-eluting stent, in the domestic market. Article

> NIH researchers are tackling the blood-brain barrier by switching off the gatekeeper molecule P-glycoprotein. Press release | Abstract

And Finally… West Pharmaceutical Services introduces its syringe safety system, which protects against needlestick injury when using a prefilled syringe. Article